Medicine and Dentistry
Gynecological Oncology
100%
Overall Survival
99%
Ovarian Cancer
87%
Disease
85%
Minimal Residual Disease
66%
Krukenberg Tumor
56%
Recurrent Disease
52%
Progression Free Survival
48%
Oncology
42%
Cancer
36%
Cervical Cancer
33%
Proteomics
31%
Neoplasm
31%
Malignant Neoplasm
28%
Program Director
28%
Adenocarcinoma
28%
Surgery
26%
Pembrolizumab
23%
Peritoneum Cancer
21%
Cytoreductive Surgery
21%
Debulking Surgery
19%
Bleeding
18%
Hysterectomy
17%
CA-125
16%
High Risk Population
16%
Endometrial Cancer
15%
Biological Marker
15%
Hazard Ratio
14%
Aggressive Angiomyxoma
14%
Disease Management
14%
Female Genital Tract Cancer
14%
Prevalence
14%
Transcriptomics
14%
Immune Checkpoint Inhibitor
14%
Disseminated Intravascular Coagulation
14%
Disease Burden
14%
COVID-19
14%
Obstetrics
14%
Placenta Accreta
14%
Needs Assessment
14%
Surgical Approach
14%
Predictive Modeling
14%
Uterine Cervix Carcinoma
14%
Social Distancing
14%
Cervix
14%
Primary Peritoneal Carcinoma
14%
Quadrantectomy
14%
Uterine Serous Carcinoma
14%
Disease Epidemiology
14%
Guillain-Barré Syndrome
14%
Keyphrases
Overall Survival
83%
Gynecologic Oncology Group
71%
Advanced Ovarian Cancer
46%
Residual Disease
42%
Uterine Serous Carcinoma
42%
NRG Oncology
42%
Progression-free Survival
40%
Ovarian Cancer
38%
Cervical Cancer
38%
Recurrence Rate
35%
Chemotherapy
32%
Minimal Residual Disease
31%
Epithelial Ovarian Cancer
29%
Stage IIIC
29%
Clinical Serum
28%
High-grade Serous Ovarian Cancer (HGSOC)
28%
Clinical Calculator
28%
Cervical Carcinoma
28%
Ancillary Data
28%
Pembrolizumab
28%
High Risk
25%
Ovarian Cancer Patients
24%
Peritoneal Cancer
23%
Primary Peritoneal Cancer
22%
Program Directors
22%
Secondary Cytoreductive Surgery
21%
Advanced Stage
21%
Disease Score
21%
High-grade Ovarian Cancer
21%
Improved Outcomes
19%
Serum Proteomics
18%
Early Recurrence
18%
5-year Survival
18%
Patient Survival
17%
Recurrence Risk
17%
Carbohydrate Antigen 125 (CA125)
17%
African American
17%
Clinical Factors
16%
Prediction Model
16%
Malignancy
16%
Serum Levels
16%
Bead Array
16%
Proteome
15%
Population Analysis
15%
Aggressive Surgery
15%
Remission
15%
Median Time
14%
Aggressive Angiomyxoma
14%
Social Distancing
14%
Clinical High Risk
14%